Kissei Pharmaceutical Co., Ltd.
Approval of Additional Indication for Iseulti for Endometriosis in Taiwan
Sihmosa (Sinmosa) obtained approval for an additional indication for the GnRH antagonist Iseulti for endometriosis in Taiwan, as part of market expansion in Taiwan. The impact on sales forecasts has already been incorporated into the consolidated earnings forecast for the fiscal year ending March 2027.
Key Figures
- Unknown: Net Sales
- Unknown: Operating Income
- Unknown: Net Income Attributable to Owners of Parent
AI要約
Impact on Performance and Background
This announcement concerns the approval in Taiwan of an additional indication for the GnRH antagonist "Iseulti" for endometriosis and reports on the status of development and marketing rights in Taiwan through Sinmosa. The additional indication application was submitted in December 2025, launch in Taiwan occurred in March 2026, and the impact has been reflected in the consolidated earnings forecast for the fiscal year ending March 2027. Future market rollout and the progress of clinical trials may affect future results.
Outlook and Impact on Shareholders
The expansion of indications in the Taiwan market is an important part of regional strategy; however, this release does not present specific sales forecasts or time-series financial metrics. Depending on future approvals, launch schedule, pricing, and progress of distribution partnerships, indirect effects on revenue and profit may be expected. Investors should note the statement that this has been incorporated into the full-year forecast for the fiscal year ending March 2027 and await additional disclosures.
Kissei Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
